NEW YORK and AMSTERDAM, Aug. 14, 2025 - atai Life Sciences $(ATAI)$ announced today that they are on track to submit an End-of-Phase 2 meeting request to the U.S. Food and Drug Administration (FDA) in the third quarter of 2025. This submission is a critical step in the regulatory review of BPL-003, an intranasal psychedelic treatment for patients with treatment-resistant depression $(TRD.UK)$. The company recently reported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003, demonstrating rapid, robust, and durable antidepressant effects for up to 8 weeks with a single dose. The anticipated regulatory milestone is part of atai's ongoing efforts to advance innovative mental health therapies.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。